Julian Kamhieh-Milz

TL;DR: Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials and suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.

TL;DR: Novel topics critical to the successful translation of MSCs from pre-clinical to clinical applications are discussed, including the major routes of cell delivery, aspects related to hemocompatibility, and potential safety concerns associated with MSC therapy in the different settings.

TL;DR: It is paramount to only use well-characterized, safe MSCs even in the most urgent and experimental treatments, and to integrate both innate and adaptive immune compatibility testing into the current guidelines for cell, tissue, and organ transplantation is critical for safe and effective therapies.

TL;DR: A reduction in fibrinolysis is identified as an important mechanism in COVID-19-associated coagulopathy and the combination of ROTEM and D-dimer concentrations may prove valuable in identifying patients requiring higher intensity anticoagulation.

TL;DR: It is concluded that in vitro aging rather than in vivo donor aging influences BMSC characteristics, and BMSCs from both cohorts meet the standard criteria for MSC, exhibiting similar morphology, growth kinetics, gene expression profiles, and pro-angiogenic and immunosuppressive potential.